Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 3/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27126273 | 1.00 | PIK3CA (0.45) | PIK3CAPPARGATML3MBTL1PDE2A | |
| SCHEMBL26881116 | 0.90 | PIK3CA (0.40) | PIK3CAPPARGATML3MBTL1ALDH1A1 | |
| SCHEMBL30742393 | 0.90 | PIK3CA (0.40) | PIK3CAPPARGATML3MBTL1ALDH1A1 | |
| SCHEMBL23887386 | 0.87 | PIK3CA (0.38) | PIK3CAPDE2A | |
| SCHEMBL31316391 | 0.87 | PIK3CA (0.38) | PIK3CAPDE2A | |
| SCHEMBL26662684 | 0.87 | PIK3CA (0.38) | PIK3CAPDE2A | |
| SCHEMBL30307526 | 0.87 | PIK3CA (0.38) | PIK3CAPDE2A | |
| SCHEMBL23887408 | 0.85 | PIK3CA (0.36) | PIK3CA | |
| SCHEMBL30584413 | 0.85 | PIK3CA (0.36) | PIK3CA | |
| SCHEMBL26881034 | 0.85 | PIK3CA (0.36) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PPARG 695/4885ATM 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.